Salim Syed
Stock Analyst at Mizuho
(2.43)
# 2,473
Out of 5,150 analysts
77
Total ratings
45.16%
Success rate
1.57%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Salim Syed
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INCY Incyte | Upgrades: Outperform | $90 → $121 | $98.22 | +23.19% | 1 | Dec 8, 2025 | |
| ASMB Assembly Biosciences | Maintains: Outperform | $29 → $40 | $28.62 | +39.76% | 2 | Nov 20, 2025 | |
| NKTX Nkarta | Maintains: Outperform | $16 → $14 | $2.70 | +418.52% | 8 | Jun 10, 2025 | |
| CYTK Cytokinetics | Maintains: Outperform | $103 → $84 | $60.87 | +38.00% | 7 | May 29, 2025 | |
| BIIB Biogen | Maintains: Outperform | $207 → $169 | $184.85 | -8.57% | 16 | May 7, 2025 | |
| AMGN Amgen | Maintains: Neutral | $235 → $280 | $373.17 | -24.97% | 8 | May 7, 2025 | |
| GILD Gilead Sciences | Maintains: Outperform | $100 → $117 | $147.80 | -20.84% | 7 | May 5, 2025 | |
| WVE Wave Life Sciences | Maintains: Outperform | $19 → $22 | $13.64 | +61.29% | 5 | Nov 21, 2024 | |
| PCVX Vaxcyte | Maintains: Outperform | $113 → $163 | $60.70 | +168.53% | 3 | Sep 10, 2024 | |
| ATRA Atara Biotherapeutics | Upgrades: Outperform | $25 → $18 | $5.38 | +234.57% | 4 | Aug 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $34 | $29.18 | +16.52% | 1 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $82 → $99 | $59.07 | +67.60% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $53 | $65.00 | -18.46% | 7 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $21 | $1.75 | +1,103.44% | 5 | Nov 16, 2022 |
Incyte
Dec 8, 2025
Upgrades: Outperform
Price Target: $90 → $121
Current: $98.22
Upside: +23.19%
Assembly Biosciences
Nov 20, 2025
Maintains: Outperform
Price Target: $29 → $40
Current: $28.62
Upside: +39.76%
Nkarta
Jun 10, 2025
Maintains: Outperform
Price Target: $16 → $14
Current: $2.70
Upside: +418.52%
Cytokinetics
May 29, 2025
Maintains: Outperform
Price Target: $103 → $84
Current: $60.87
Upside: +38.00%
Biogen
May 7, 2025
Maintains: Outperform
Price Target: $207 → $169
Current: $184.85
Upside: -8.57%
Amgen
May 7, 2025
Maintains: Neutral
Price Target: $235 → $280
Current: $373.17
Upside: -24.97%
Gilead Sciences
May 5, 2025
Maintains: Outperform
Price Target: $100 → $117
Current: $147.80
Upside: -20.84%
Wave Life Sciences
Nov 21, 2024
Maintains: Outperform
Price Target: $19 → $22
Current: $13.64
Upside: +61.29%
Vaxcyte
Sep 10, 2024
Maintains: Outperform
Price Target: $113 → $163
Current: $60.70
Upside: +168.53%
Atara Biotherapeutics
Aug 16, 2024
Upgrades: Outperform
Price Target: $25 → $18
Current: $5.38
Upside: +234.57%
Apr 9, 2024
Initiates: Buy
Price Target: $34
Current: $29.18
Upside: +16.52%
Mar 6, 2024
Maintains: Buy
Price Target: $82 → $99
Current: $59.07
Upside: +67.60%
Mar 5, 2024
Maintains: Buy
Price Target: $60 → $53
Current: $65.00
Upside: -18.46%
Nov 16, 2022
Maintains: Buy
Price Target: $28 → $21
Current: $1.75
Upside: +1,103.44%